MEDPMedpace Holdings, Inc.
$669.27+28% 1Y
$669.27
$393.4252 weeks$669.27
Latest close: a new 52-week highOct 23, 2026what changed →
The financials
Medpace Holdings, Inc. by the numbers
Medpace Holdings, Inc. (MEDP) reported revenue of $716M in Q3 2026 (quarter ended Sep 30, 2026), up 8.5% from the same quarter a year earlier. That came with a gross margin of 31% and net income of $137M (19% of revenue). For the full year FY2025, revenue was $2.53B (+20% year on year) and net income $451M. Its largest product in Q2 2026 (quarter ended Jun 30, 2026) was Metabolic at $219M, 31% of the disclosed total, just ahead of Oncology at 30%. The next results filing is expected around Feb 8, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $716M | $660M | +8.5% |
| Gross profit | $224M | $197M | +14% |
| Operating income | $166M | $142M | +17% |
| Net income | $137M | $111M | +24% |
| Diluted EPS | $4.84 | $3.86 | +25% |
| Product | Revenue | Share |
|---|---|---|
| Metabolic | $219M | 31% |
| Oncology | $209M | 30% |
| Other | $98M | 14% |
| Central Nervous System | $83M | 12% |
| Cardiology | $60M | 8.5% |
| Antiviral And Anti Infective | $38M | 5.3% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $707.3M (+0.10%)
Metabolic grew +48% year on yearOther -17% year on year
Segment Latestquarter on quarteryear on year
- Metabolic$219.1M$219.1Mquarter on quarter -7.8%year on year +48%-7.8%+48%
- Oncology$209.4M$209.4Mquarter on quarter +4.0%year on year +11%+4.0%+11%
- Other$98.3M$98.3Mquarter on quarter +5.3%year on year -17%+5.3%-17%
- Central Nervous System$82.9M$82.9Mquarter on quarter +3.3%year on year +36%+3.3%+36%
- Cardiology$60.0M$60.0Mquarter on quarter +6.6%year on year +2.4%+6.6%+2.4%
- Antiviral And Anti Infective$37.8M$37.8Mquarter on quarter -0.65%year on year +30%-0.65%+30%
Diagnostics & Research
Ranks #1 of 21 by RyuScore